Navigation Links
Ampio Pharmaceuticals Announces Closing of Public Offering
Date:7/18/2012

GREENWOOD VILLAGE, Colo., July 18, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ & Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced the closing of a $17,839,120 underwritten public offering of 5,488,960 shares of common stock, including 692,310 shares of common stock which were sold by Ampio and certain of its stockholders pursuant to the exercise of the underwriters' over-allotment option, at a price of $3.25 per share.  Ampio received gross proceeds of $16,912,545 from the offering and the selling stockholders received gross proceeds of $926,575 from the offering.  Ampio will not receive any of the proceeds from the sale of shares by the selling stockholders.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Aegis Capital Corp. and Fordham Financial Management, Inc. acted as joint book-running managers for the offering.

The offering was made pursuant to a shelf registration statement that Ampio filed with the Securities and Exchange Commission ("SEC") and is effective.  The prospectus supplements relating to the offering were filed with the SEC and are available on the website of the SEC at http://www.sec.gov.  Copies of the prospectus supplements relating to the offering may also be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com or Fordham Financial Management, Inc., 17 Battery Place, South, Suite 643, New York, New York 10004.  

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact: Rick Giles, Investor Relations, Ampio Pharmaceuticals, Inc. 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Ampio Pharmaceuticals Schedules 2012 Update Webcast
4. Four-Time Triathlon World Champion Melanie McQuaid Selects Polar USA as Official Heart Rate Training Solution
5. Ampios CEO and CSO Send Message to Shareholders
6. Ampio Pharmaceuticals Announces Proposed Public Offering
7. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
8. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
9. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/9/2017)... WARSAW, Ind. , May 9, 2017 ... global leader in musculoskeletal healthcare, today announced it has ... Large Employers of 2017" list. The Company was ranked ... categories of Large Employers and Healthcare Equipment and Services. ... U.S. employers based on an anonymous, independent survey of ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... ... at Boston CEO 2017 on May 30th and 31st at The Four Seasons ... for leading executives in the life sciences, offering exclusive access to key decision ...
(Date:5/26/2017)... , ... May 26, 2017 , ... A new analysis ... with the healthiest seniors are located in the Midwest. With the average cost of ... more people are concerned with both the quality and affordability of where they live. ...
(Date:5/26/2017)... ... , ... After raising nearly $30,000 on Kickstarter , about three-times its ... a discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress ... bring a fidget toy to the market that was made of superior quality and ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... ... Garden of Eden”: retells the stories of three Bible figures in modern terms. “Just ... mother, trader, horse farmer, artist and a former GM journeyman. Born in 1953 in ... moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured France ...
Breaking Medicine News(10 mins):